We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going to take a look at where Absci (NASDAQ:ABSI) stands against other AI companies under $2 billion market cap.
It’s clear that AI holds immense promise but it comes with significant risks. Some of the concerns that the market has include overreliance on a few key players, shifts in demand toward smaller competitors, and the broader impact of AI-driven market trends on earnings and valuations. While AI offers opportunities, managing risks such as customer concentration, economic headwinds, and market volatility will be crucial for its sustainable growth and integration.
Navigating AI Expectations and Market Dynamics
On CNBC ‘Fast Money,’ a discussion between traders highlighted concerns about elevated expectations for AI, especially in the chip market, with NVDA as a prime example. Past patterns in the semiconductor giant’s stock suggest potential declines, with customer concentration being a significant risk. Some believe demand for high-end chips could shift to smaller semiconductor companies. They also discussed that broader market performance might improve as other sectors gain traction, especially during earnings season, which is expected to influence investor sentiment more than AI and GLP-1 trends.
They mentioned that the key risks for earnings include the strong U.S. dollar, rising rates, and policy uncertainties, which may impact large-cap companies. While recent PPI data offered some relief, the bond market remains firm, with 10-year yields approaching 5%. Expectations for CPI and PCE figures are mixed, with potential reacceleration seen as a headwind for markets in a higher rate environment. Earnings and economic data were considered critical factors to watch by the traders.
Our Methodology
For this article, we scoured our database as well as several ETFs and media reports to find all possible AI stocks under $2 billion. We then listed the stocks in ascending order of their market cap. We also added the hedge fund sentiment around each stock which was taken from Insider Monkey’s database of 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A scientist in a lab, focused on a molecular microscope with biologic drug candidates.
Absci Corporation (NASDAQ:ABSI)
Market Capitalization: $320.33 Million
Number of Hedge Fund Holders: 20
Absci Corporation (NASDAQ:ABSI) is a generative AI drug creation company that integrates AI with scalable wet lab technologies to develop biologics more efficiently. Its Integrated Drug Creation platform accelerates drug development by optimizing multiple characteristics critical for both development and therapeutic success. The company can screen billions of cells weekly, enabling it to go from AI-designed antibodies to wet lab-validated candidates in just six weeks.
Absci (NASDAQ:ABSI) recently achieved a few milestones in healthcare AI as it received a $20 million investment from AMD to support Absci’s AI-driven drug discovery initiatives. In addition, the company also partnered with Owkin to combine their AI-driven platforms to accelerate the discovery and design of novel therapeutics. Absci’s generative AI Drug Creation platform and Owkin’s predictive AI target discovery technology will work together to address new targets in immuno-oncology and other areas like immunology and inflammation.
Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Absci (NASDAQ:ABSI) with a $7.00 price target. The rating reflects the strategic partnership with AMD for better AI-driven antibody development and the promising progress of AbSci’s internal pipeline, with key upcoming data points. The target is based on projected revenues and a conservative growth outlook.
Overall, ABSI ranks 26th on ourlist of the 59 AI companies under $2 billion market cap. While we acknowledge the potential of ABSI as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ABSI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
